Abstract
Purpose
The aim of this study was to evaluate, by means of 123I-FP-CIT SPECT, the effect of chronic treatment with levodopa on striatal dopamine transporter (DAT) in patients with Parkinson’s disease.
Methods
Fifteen patients under stable levodopa/carbidopa monotherapy were imaged twice: at baseline on medication and after at least 20 days of treatment wash-out. DAT levels were assessed from SPECT imaging for the entire striatum, the right and left striatum, the right and left putamen and the right and left caudate, as a ratio of regional brain activities using the formula: (striatal region of interest−occipital)/occipital.
Results
During levodopa wash-out, despite a worsening in patients’ clinical disability (H&Y mean stage 2.53±0.58 versus 1.73±0.45 on therapy, p<0.001), striatal 123I-FP-CIT levels were not significantly different from those at baseline in any of the brain regions examined.
Conclusion
The results of this study suggest that levodopa does not affect 123I-FP-CIT brain imaging and confirm that it is not necessary to withdraw this medication to measure DAT levels with SPECT.
Similar content being viewed by others
References
Seibyl JP. Imaging studies in movement disorders. Semin Nucl Med 2003;33:105–13
Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415–23
Bohnen NI, Frey KA. The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am 2003;4:791–803
Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson’s disease. Eur J Nucl Med 1997;24:68–71
Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692–8
Innis RB, Marek KL, Sheff K, Zoghbi S, Castronuovo J, Feigin A, et al. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]β-CIT. Mov Disord 1999;14:436–42
Ahlskog JE, Uitti RJ, O’Connor MK, Maraganore DM, Matsumoto JY, Stark KF, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson’s disease. Mov Disord 1999;14:940–6
Tatsch K, Asenbaum S, Bartenstein P, Halldin C, Pilowski L, Pupi A, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30–5
Lavalaye J, Knol RJ, de Bruin K, Reneman L, Janssen AG, Booij J. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. Eur J Nucl Med 2000;27:346–9
Daniel SE, Lees AJ. Parkinon’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165–72
Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne D, Golstein M, editors. Recent developments in Parkinson’s disease. Florham Park, NJ: Macmillan Healthcare Information; 1987; p. 153–164
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42
Chang LT. A method for attenuation correction in computed tomography. IEEE Trans Nucl Sci 1987;NS-25:638–43
Marek K, Jennings D, Seibyl J. Dopamine agonists and Parkinson’s disease progression: what can we learn from neuroimaging studies? Ann Neurol 2003;53 Suppl 3:S160–6
Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord 2003;18 Suppl 7:S63–70
Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559–64
Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604–9
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653–61
The Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med 2004;351:2498–508
Muenter MD, Tyce GM. L-Dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231–9
Nutt JG, Carter JH, Woodward WR. Long-duration response to levodopa. Neurology 1995;45:1613–6
Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early onset Parkinson’s disease. Mov Disord 2002;17:961–8
Nutt JG. Long term l-dopa therapy: challenges to our understanding and for the care of people with Parkinson’s disease. Exp Neurol 2003;184:9–13
Nutt JG, Holford NHG. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann Neurol 1996;39:561–73
Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of deprenil and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995;38:771–7
Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later l-dopa. Arch Neurol 1999;56:529–35
Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptina in early Parkinson’s disease. Mov Disord 2000;15:485–9
Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999;26:171–82
Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 1998;39:1879–84
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schillaci, O., Pierantozzi, M., Filippi, L. et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson’s disease. Eur J Nucl Med Mol Imaging 32, 1452–1456 (2005). https://doi.org/10.1007/s00259-005-1922-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-005-1922-9